{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:32:09Z","timestamp":1790526729671,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["572516"],"award-info":[{"award-number":["572516"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1057762"],"award-info":[{"award-number":["1057762"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical and Health Research Infrastructure Fund"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","exphem.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.exphem.2016.02.008","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T08:38:34Z","timestamp":1456475914000},"page":"410-421.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dasatinib promotes the activation of quiescent hematopoietic stem cells in\u00a0mice"],"prefix":"10.1016","volume":"44","author":[{"given":"Johanna M.","family":"Duyvestyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha A.","family":"Dagger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace Y.","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2016.02.008_bib1","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1517\/14656566.2012.725722","article-title":"Dasatinib for the treatment of Philadelphia chromosome-positive leukemias","volume":"13","author":"Santos","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.exphem.2016.02.008_bib2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.02.008_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.02.008_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2016.02.008_bib5","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","article-title":"Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors","volume":"17","author":"Montero","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2016.02.008_bib6","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/blood-2012-09-457119","article-title":"Targeting the LYN\/HS1 signaling axis in chronic lymphocytic leukemia","volume":"121","author":"ten Hacken","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.02.008_bib7","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","article-title":"Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia","volume":"17","author":"Amrein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2016.02.008_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-2-4","article-title":"Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma","volume":"2","author":"Boukhiar","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.exphem.2016.02.008_bib9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bjh.12573","article-title":"Bruton tyrosine kinase inhibitors: A promising novel targeted treatment for B cell lymphomas","volume":"163","author":"Aalipour","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2016.02.008_bib10","first-page":"27","article-title":"Dasatinib. Recent results in cancer research. Fortschritte der Krebsforschung","volume":"201","author":"Lindauer","year":"2014","journal-title":"Progres dans les recherches sur le cancer"},{"key":"10.1016\/j.exphem.2016.02.008_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.exphem.2015.01.008","article-title":"The targeting of human and mouse B lymphocytes by dasatinib","volume":"43","author":"Oksvold","year":"2015","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2016.02.008_bib12","doi-asserted-by":"crossref","first-page":"e94717","DOI":"10.1371\/journal.pone.0094717","article-title":"Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice","volume":"9","author":"Duyvestyn","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2016.02.008_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccr.2010.09.008","article-title":"Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling","volume":"18","author":"Rathinam","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2016.02.008_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.174.1.63","article-title":"Expression and function of c-kit in hemopoietic progenitor cells","volume":"174","author":"Ogawa","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2016.02.008_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.exphem.2006.10.001","article-title":"Heterozygous kit mutants with little or no apparent anemia exhibit large defects in overall hematopoietic stem cell function","volume":"35","author":"Sharma","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2016.02.008_bib16","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/stem.1419","article-title":"KIT receptor gain-of-function in hematopoiesis enhances stem cell self-renewal and promotes progenitor cell expansion","volume":"31","author":"Deshpande","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2016.02.008_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nature13824","article-title":"Clonal dynamics of native haematopoiesis","volume":"514","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2016.02.008_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.stem.2015.05.003","article-title":"Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions","volume":"17","author":"Pietras","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2016.02.008_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1084\/jem.20131128","article-title":"High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias","volume":"211","author":"Shin","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2016.02.008_bib20","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1182\/blood-2012-06-436675","article-title":"Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling","volume":"120","author":"Taylor","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.02.008_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1084\/jem.20131043","article-title":"Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons","volume":"211","author":"Pietras","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2016.02.008_bib22","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in\u00a0vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2016.02.008_bib23","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1517\/14656566.2011.597741","article-title":"The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose","volume":"12","author":"Breccia","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.exphem.2016.02.008_bib24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-09-2416","article-title":"Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias","volume":"16","author":"Guerrouahen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2016.02.008_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canlet.2009.03.035","article-title":"Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling","volume":"283","author":"Nautiyal","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.exphem.2016.02.008_bib26","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-05-0757","article-title":"Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells","volume":"11","author":"Johnson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2016.02.008_bib27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","article-title":"Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche","volume":"1","author":"Yoshihara","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2016.02.008_bib28","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood-2012-11-466425","article-title":"The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents","volume":"122","author":"Dos Santos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.02.008_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.leukres.2008.09.027","article-title":"Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V","volume":"33","author":"Ustun","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2016.02.008_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MOH.0000000000000124","article-title":"Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia","volume":"22","author":"Ustun","year":"2015","journal-title":"Curr Opin Hematol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X16000722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X16000722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T21:52:08Z","timestamp":1536961928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X16000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0301472X16000722"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2016.02.008","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib promotes the activation of quiescent hematopoietic stem cells in\u00a0mice","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2016.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}